
Releases
PTC Therapeutics Targets $500 Million Debt Refinancing
PTC Therapeutics is launching a $500 million private offering of convertible senior notes due in 2031. The biopharmaceutical company plans to use the capital to retire its existing 2026 debt obligations while simultaneously executing a $50 million common stock buyback program to manage its equity capital structure.
























